PitchSend

Nuvectis Pharma Investor Presentation Deck

Nuvectis Investment Highlights Precision medicine pipeline for serious conditions of unmet medical need in oncology 2024 Milestones NXP800 NXP900 Management Team with Strong Track Record NuvectisPharma, Inc. H x T Preliminary clinical data for NXP800 (ARID1a-mutated ovarian cancer and cholangiocarcinoma) and for NXP900 (Phase 1a study) Presentations at medical and scientific conferences ARID1a mutated, platinum resistant ovarian cancer - Phase 1b ongoing Cholangiocarcinoma - IST/Mayo Clinic commenced Highly selective compound, differentiated from other YES1/SRC-kinase inhibitors Phase 1a ongoing 3 approved drugs in 4 indications in the US, EU approvals and multiple strategic deals Generated significant shareholder value 24

View entire presentation